Jones Financial Companies Lllp grew its holdings in shares of Medtronic plc. (NYSE:MDT) by 1.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 79,813 shares of the medical technology company’s stock after buying an additional 936 shares during the quarter. Jones Financial Companies Lllp’s holdings in Medtronic were worth $6,445,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also modified their holdings of the company. Willis Investment Counsel boosted its holdings in Medtronic by 0.3% during the second quarter. Willis Investment Counsel now owns 97,961 shares of the medical technology company’s stock worth $8,694,000 after purchasing an additional 296 shares during the last quarter. Mariner Wealth Advisors LLC boosted its holdings in Medtronic by 9.3% during the second quarter. Mariner Wealth Advisors LLC now owns 17,239 shares of the medical technology company’s stock worth $1,530,000 after purchasing an additional 1,463 shares during the last quarter. GQG Partners LLC purchased a new position in Medtronic during the second quarter worth about $4,392,000. Bluestein R H & Co. boosted its holdings in Medtronic by 6.3% during the second quarter. Bluestein R H & Co. now owns 318,231 shares of the medical technology company’s stock worth $28,243,000 after purchasing an additional 18,764 shares during the last quarter. Finally, South Street Advisors LLC boosted its holdings in Medtronic by 768.2% during the second quarter. South Street Advisors LLC now owns 112,509 shares of the medical technology company’s stock worth $9,985,000 after purchasing an additional 99,550 shares during the last quarter. Hedge funds and other institutional investors own 80.79% of the company’s stock.
Shares of Medtronic plc. (NYSE MDT) opened at $83.15 on Monday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 2.09 and a current ratio of 2.43. The firm has a market cap of $112,699.27, a P/E ratio of 17.73, a P/E/G ratio of 2.36 and a beta of 0.97. Medtronic plc. has a twelve month low of $76.51 and a twelve month high of $89.72.
In other Medtronic news, VP Richard Kuntz sold 78,526 shares of the business’s stock in a transaction that occurred on Tuesday, January 9th. The shares were sold at an average price of $86.21, for a total value of $6,769,726.46. Following the completion of the transaction, the vice president now owns 149,761 shares of the company’s stock, valued at approximately $12,910,895.81. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, SVP Carol A. Surface sold 24,479 shares of the business’s stock in a transaction that occurred on Monday, March 5th. The stock was sold at an average price of $78.18, for a total transaction of $1,913,768.22. The disclosure for this sale can be found here. In the last three months, insiders sold 145,163 shares of company stock valued at $12,232,045. Corporate insiders own 0.31% of the company’s stock.
Several research analysts recently weighed in on the stock. Stifel Nicolaus boosted their price target on shares of Medtronic from $83.00 to $85.00 and gave the stock a “hold” rating in a report on Wednesday, November 22nd. Oppenheimer restated a “buy” rating and set a $94.00 price target on shares of Medtronic in a report on Wednesday, November 22nd. Argus upgraded shares of Medtronic from a “hold” rating to a “buy” rating and boosted their price target for the stock from $81.27 to $95.00 in a report on Tuesday, December 12th. They noted that the move was a valuation call. Morgan Stanley boosted their price target on shares of Medtronic from $91.00 to $95.00 and gave the stock an “equal weight” rating in a report on Monday, February 5th. Finally, Evercore ISI assumed coverage on shares of Medtronic in a report on Wednesday, January 3rd. They set an “outperform” rating and a $92.50 price target on the stock. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and sixteen have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $91.50.
TRADEMARK VIOLATION WARNING: “Jones Financial Companies Lllp Has $6.45 Million Stake in Medtronic plc. (MDT)” was published by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international trademark and copyright law. The original version of this piece of content can be read at https://www.americanbankingnews.com/2018/03/12/jones-financial-companies-lllp-has-6-45-million-stake-in-medtronic-plc-mdt.html.
Medtronic Company Profile
Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.